The cycling of combination antirheumatic drug therapy in rheumatoid arthritis.
In this open pilot study a combination of hydroxychloroquine, prednisolone and alternating months of treatment with sulphasalazine or oral weekly pulse methotrexate has been investigated in 16 patients with rheumatoid arthritis (RA) refractory to a total of 67 disease suppressive medications. Results at 3 months indicated significant improvements in visual analogue score for pain, joint count, Ritchie index, scale of disability related to activities of daily living, ESR, rheumatoid factor and C-reactive protein. This degree of improvement, however, was not maintained 6 and 12 months after commencement of treatment. Pain score, Ritchie index and ESR were the only parameters demonstrating significant improvement at 12 months. Therapy was terminated in eight patients, half due to lack of efficacy and half because of side effects.
Schwarzer
A C
AC
Sydney University Department of Rheumatology, NSW, Australia.
Arnold
M H
MH
Kelly
D
D
Jones
M
M
Beller
E
E
McNaught
P J
PJ
Schrieber
L
L
Brooks
P M
PM
D000203:Activities of Daily Living; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D002097:C-Reactive Protein / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010865:Pilot Projects; D012217:Rheumatoid Factor / Q000032:analysis; D012720:Severity of Illness Index; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D002097:C-Reactive Protein; D012217:Rheumatoid Factor